Drug Profile


Alternative Names: DU-176; DU-176b; Edoxaban tosilate hydrate; Edoxaban tosylate; LIXIANA; Lixiana; Roteas; SAVAYSA

Latest Information Update: 24 Jul 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation; Embolism; Stroke; Venous thromboembolism
  • Registered Deep vein thrombosis; Pulmonary embolism
  • Phase I Venous thrombosis

Most Recent Events

  • 17 Jul 2017 CHMP recommends label update to provide guidance on edoxaban use in patients for Atrial fibrillation undergoing cardioversion in European Union
  • 19 Jun 2017 Daiichi Sankyo initiates enrolment in the phase III ENVISAGE TAVI-AF trial for Atrial fibrillation in Spain (PO) (EudraCT2016-003930-26)
  • 08 May 2017 Launched for Atrial fibrillation and Venous thromboembolism in Thailand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top